Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA Nano Antibody CAR-T in Relapsed/Refractory Multiple Myeloma
NCT03661554Phase 1Unknown
- Sponsor
- Shenzhen Puruijin Biological Pharmaceutical Co., Ltd.
- Start
- Apr 2018
- Primary completion
- Oct 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-BCMA CAR-T (sdAb) in multiple myeloma (MM), sponsored by Shenzhen Puruijin Biological Pharmaceutical Co., Ltd. Primary endpoint: Number of participants with treatment-related adverse events at 2 years. Status: unknown.
02
Drugs
anti-BCMA CAR-T (sdAb)
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03661554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03661554.